AGM
AGRX

Alpine Global Management’s Agile Therapeutics AGRX Stock Holding History

Alpine Global Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7
Closed -$18K – 399
2021
Q2 		$18K Buy
+7
New +$23.1K ﹤0.01% 300
2020
Q2 		– Sell
-6
Closed -$24K – 440
2020
Q1 		$24K Buy
+6
New +$34.4K 0.01% 207
2018
Q1 		– Sell
-11
Closed -$59K – 208
2017
Q4 		$59K Buy
+11
New +$102K 0.01% 178

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alpine Global Management's AGRX Position: Q3 2021 in Review

Alpine Global Management sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 7 shares — an estimated $18K sold.

Alpine Global Management first reported a position in AGRX in Q4 2017 and held it in 3 quarters. The position peaked at $59K in Q4 2017. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Alpine Global Management reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Alpine Global Management sold 7 Agile Therapeutics shares in Q3 2021, an estimated $18K.
  • Alpine Global Management first reported a position in Agile Therapeutics in Q4 2017 and held it in 3 quarters.
  • Alpine Global Management's Agile Therapeutics position peaked at $59K in Q4 2017.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Alpine Global Management's 13F filing for Q3 2021, filed 12 Nov 2021.